Literature DB >> 9841760

Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery--prospective double-blind placebo-controlled study.

N Qvist1, S Boesby, B Wolff, C P Hansen.   

Abstract

In a double-blind placebo-controlled study we investigated the effect of recombinant human erythropoietin (r-HuEPO), on the perioperative hemoglobin concentration and the use of blood transfusions in patients undergoing elective colorectal surgery with a preoperative hemoglobin level </=8.5 mmol/L. Altogether 100 were included, and 81 patients could be evaluated. A total of 38 patients received r-HuEPO in a dose of 300 IU/kg body weight on day 4 before surgery and 150 IU/kg daily for the following 7 days; 43 patients received placebo. In addition, all patients received daily doses of 200 mg iron orally for 4 days before surgery. There were no differences between the two groups with regard to sex, height, weight, serum electrolytes, and liver function tests at study entry. The preentry hemoglobin concentration was similar in the two groups, with a median value of 7.9 (range 5.3-8.5) mmol/L in the erythropoietin group and 7.6 (5.1-8.5) mmol/L in the placebo group. On the day of surgery the median hemoglobin concentration was 7.8 (5. 3-9.2) mmol/L in the erythropoietin group and 7.2 (4.6-8.5) mmol/L in the placebo group (p < 0.05). On postoperative days 3 and 7 the values were 7.2 (5.3-8.2) and 7.5 (5.4-9.4) mmol/L, respectively, in the erythropoietin group compared to 6.7 (5.2-7.8) and 6.9 (5.1-8.6) mmol/L in the placebo group (p < 0.01). At discharge the hemoglobin concentration was 7.8 (5.9-8.8) mmol/L in the erythropoietin group and 7.2 (5.4-8.6) mmol/L in the placebo group (p < 0.002). The blood loss during operation was similar in the two groups. In the erythropoietin group the median value was 280 ml (range 25-2000 ml), with the lower and upper quartiles 150 and 500 ml, respectively. In the placebo group the blood loss was median 300 ml (range 50-1800 ml), with the lower and upper quartiles 200 and 750 ml, respectively. The number of blood transfusions given was significantly lower in the erythropoietin group, with a mean of 0.3 (range 0-6) units compared to 1.6 (0-9) units in the control group (p < 0.05). In conclusion, the hemoglobin concentration at the time of surgery and during the week following surgery was significantly higher in the group of patients receiving r-HuEPO perioperatively compared to the placebo group together with a significant lower use of blood transfusions in the r-HuEPO group. However, the clinical implications of these findings has yet to be proven.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9841760     DOI: 10.1007/s002689900561

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  10 in total

1.  Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".

Authors:  Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

Review 2.  Perioperative anemia management in colorectal cancer patients: a pragmatic approach.

Authors:  Manuel Muñoz; Susana Gómez-Ramírez; Elisa Martín-Montañez; Michael Auerbach
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 3.  [Diagnostics and treatment of preoperative anemia].

Authors:  C Rosenthal; C von Heymann; L Kaufner
Journal:  Anaesthesist       Date:  2019-08       Impact factor: 1.041

4.  Need for preoperative anemia management clinics in Japan: initiatives at a university hospital in the USA.

Authors:  Patrick Hussey; Yoshiko Onodera; Sundara Reddy; Blain Samuelson; Sudhakar Subramani; Yatish Siddapura Ranganath; Tariq Jaradat; Satoshi Hanada
Journal:  J Anesth       Date:  2021-08-02       Impact factor: 2.078

Review 5.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Authors:  Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach
Journal:  CMAJ       Date:  2009-04-30       Impact factor: 8.262

Review 6.  [Perioperative anemia management: a systematic review and meta-analysis].

Authors:  Anna Glechner; Gerald Gartlehner; Barbara Nußbaumer; Sibylle Kozek-Langenecker
Journal:  Wien Med Wochenschr       Date:  2014-08-29

7.  Pre-operative iron increases haemoglobin concentration before abdominal surgery: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jeremy Meyer; Roberto Cirocchi; Salomone Di Saverio; Frédéric Ris; James Wheeler; Richard Justin Davies
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.996

8.  Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.

Authors:  Jorien Laermans; Hans Van Remoortel; Bert Avau; Geertruida Bekkering; Jørgen Georgsen; Paola Maria Manzini; Patrick Meybohm; Yves Ozier; Emmy De Buck; Veerle Compernolle; Philippe Vandekerckhove
Journal:  Syst Rev       Date:  2022-10-17

Review 9.  Preoperative recombinant human erythropoietin in anemic surgical patients.

Authors:  Terri G Monk
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

10.  Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery.

Authors:  Lutz Kaufner; Christian von Heymann; Anne Henkelmann; Nathan L Pace; Stephanie Weibel; Peter Kranke; Joerg J Meerpohl; Ravi Gill
Journal:  Cochrane Database Syst Rev       Date:  2020-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.